MX2022005827A - Derivados de pirazol como inhibidores de malt1. - Google Patents
Derivados de pirazol como inhibidores de malt1.Info
- Publication number
- MX2022005827A MX2022005827A MX2022005827A MX2022005827A MX2022005827A MX 2022005827 A MX2022005827 A MX 2022005827A MX 2022005827 A MX2022005827 A MX 2022005827A MX 2022005827 A MX2022005827 A MX 2022005827A MX 2022005827 A MX2022005827 A MX 2022005827A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrazole derivatives
- malt1 inhibitors
- malt1
- inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se describen compuestos, composiciones y métodos para tratar enfermedades, síndromes, condiciones o trastornos que son afectados por la modulación de MALT1. Tales compuestos se representan mediante la Fórmula (I): (ver Fórmula) Fórmula (I) en donde R1, R2, R3, R4, R5, R6, R5, G1, y G2 se definen en la presente descripción.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662437384P | 2016-12-21 | 2016-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005827A true MX2022005827A (es) | 2022-06-08 |
Family
ID=61628454
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019007540A MX2019007540A (es) | 2016-12-21 | 2017-12-20 | Derivados de pirazol como inhibidores de malt1. |
MX2022005827A MX2022005827A (es) | 2016-12-21 | 2019-06-21 | Derivados de pirazol como inhibidores de malt1. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019007540A MX2019007540A (es) | 2016-12-21 | 2017-12-20 | Derivados de pirazol como inhibidores de malt1. |
Country Status (22)
Country | Link |
---|---|
US (2) | US10954214B2 (es) |
EP (1) | EP3558969A1 (es) |
JP (1) | JP7138641B2 (es) |
KR (1) | KR102583317B1 (es) |
CN (1) | CN110214136A (es) |
AR (1) | AR110421A1 (es) |
AU (2) | AU2017382185C1 (es) |
BR (1) | BR112019012355A2 (es) |
CA (1) | CA3048027A1 (es) |
CL (1) | CL2019001709A1 (es) |
CO (1) | CO2019006622A2 (es) |
EA (1) | EA201991503A1 (es) |
IL (1) | IL267343B2 (es) |
MA (1) | MA47125A (es) |
MX (2) | MX2019007540A (es) |
PE (1) | PE20191755A1 (es) |
PH (1) | PH12019501212A1 (es) |
TN (1) | TN2019000192A1 (es) |
TW (1) | TWI795381B (es) |
UA (1) | UA127920C2 (es) |
UY (1) | UY37537A (es) |
WO (1) | WO2018119036A1 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
UA126113C2 (uk) | 2015-12-22 | 2022-08-17 | Інсайт Корпорейшн | Гетероциклічні сполуки як імуномодулятори |
MA44860A (fr) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
CA3028685A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為malt1抑制劑之吡唑衍生物 |
WO2018119266A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CA3073656C (en) | 2017-09-22 | 2024-03-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
SG11202004143XA (en) | 2017-11-06 | 2020-06-29 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
CN111542523B (zh) | 2017-11-24 | 2024-03-29 | 朱比连特埃皮斯科瑞有限责任公司 | 作为prmt5抑制剂的杂环化合物 |
CA3093527A1 (en) | 2018-03-13 | 2019-09-19 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
IL313101A (en) | 2018-03-30 | 2024-07-01 | Incyte Corp | Heterocyclic compounds as immunomodulators |
TWI821288B (zh) | 2018-05-11 | 2023-11-11 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
MX2020013899A (es) * | 2018-06-18 | 2021-05-27 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de malt1. |
CA3104055A1 (en) * | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyrazole derivatives as malt1 inhibitors |
TW202045008A (zh) * | 2019-02-01 | 2020-12-16 | 印度商皮埃企業有限公司 | 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途 |
US20220127249A1 (en) | 2019-02-22 | 2022-04-28 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
MA55015A (fr) | 2019-02-22 | 2021-12-29 | Janssen Pharmaceutica Nv | Formulations pharmaceutiques |
US20220162187A1 (en) | 2019-04-11 | 2022-05-26 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as malt1 inhibitors |
EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
WO2021080015A1 (en) * | 2019-10-24 | 2021-04-29 | Ono Pharmaceutical Co., Ltd. | Modulators of trek (twik related k+ channels) channel function |
CN114829366A (zh) | 2019-11-11 | 2022-07-29 | 因赛特公司 | Pd-1/pd-l1抑制剂的盐及结晶形式 |
JP2023503101A (ja) * | 2019-11-22 | 2023-01-26 | ヤンセン ファーマシューティカ エヌ.ベー. | Malt1阻害剤の有効性を評価するためのnf-kb調節遺伝子発現アッセイ |
KR20220116460A (ko) * | 2019-11-22 | 2022-08-23 | 얀센 파마슈티카 엔.브이. | NF-kB 전좌 분석을 사용하여 MALT1 억제제의 효능을 평가하기 위한 방법 |
WO2021138298A1 (en) * | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
WO2021262969A1 (en) | 2020-06-24 | 2021-12-30 | The General Hospital Corporation | Materials and methods of treating cancer |
KR20230054394A (ko) | 2020-08-21 | 2023-04-24 | 얀센 파마슈티카 엔.브이. | 비정질 형태의 malt1 억제제 및 이의 제형 |
AU2021329842A1 (en) | 2020-08-21 | 2023-05-04 | Janssen Pharmaceutica Nv | Pharmaceutical formulations comprising a malt1 inhibitor and a mixture of polyethylene glycol with a fatty acid |
TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之結晶形式 |
CN116670114A (zh) | 2020-11-06 | 2023-08-29 | 因赛特公司 | 用于制备pd-1/pd-l1抑制剂以及其盐和结晶形式的方法 |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
US20230414629A1 (en) * | 2020-11-12 | 2023-12-28 | Monopteros Therapeutics, Inc. | Materials and methods of treating cancer |
GB202018412D0 (en) | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
US20240132475A1 (en) * | 2021-02-04 | 2024-04-25 | Aurigene Oncology Limited | Substituted pyrazolyl compounds as malt-1 inhibitors |
CA3212015A1 (en) | 2021-03-03 | 2022-09-09 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
JP2024508890A (ja) | 2021-03-03 | 2024-02-28 | ヤンセン ファーマシューティカ エヌ.ベー. | 治療有効用量のmalt1阻害剤jnj-67856633(1-(1-オキソ-1,2-ジヒドロイソキノリン-5-イル)-5-(トリフルオロメチル)-n-(2-(トリフルオロメチル)ピリジン-4-イル)-1h-ピラゾール-4-カルボキサミド)を使用して状態を治療する方法 |
CN117120427A (zh) * | 2021-06-18 | 2023-11-24 | 上海拓界生物医药科技有限公司 | 一种malt1抑制剂及其制备方法和用途 |
EP4368618A1 (en) * | 2021-07-05 | 2024-05-15 | Betta Pharmaceuticals Co., Ltd | Six-membered aryl or heteroaryl amides, and composition and use thereof |
CA3227033A1 (en) | 2021-08-09 | 2023-02-16 | Eric Frederik ELDERING | Compositions for use in treating b-cell malignancies |
CN113912511B (zh) * | 2021-11-29 | 2024-02-13 | 广东广康生化科技股份有限公司 | 一种联苯肼酯中间体的合成方法 |
WO2023125877A1 (zh) | 2021-12-30 | 2023-07-06 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
WO2023148501A1 (en) * | 2022-02-03 | 2023-08-10 | C4X Discovery Limited | Heterocyclic derivatives as malt1 inhibitors |
WO2024068947A1 (en) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2024068950A1 (en) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
WO2024115512A1 (en) | 2022-11-30 | 2024-06-06 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline derivatives |
WO2024125628A1 (zh) * | 2022-12-16 | 2024-06-20 | 江苏恒瑞医药股份有限公司 | 一种Malt 1抑制剂的磷酸酯前药 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
GB9721964D0 (en) * | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
EP1451160B1 (en) | 2001-11-01 | 2010-01-13 | Icagen, Inc. | Pyrazole-amides for use in the treatment of pain |
CA2522994C (en) * | 2003-04-30 | 2012-09-25 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer |
EP2133348B1 (en) | 2003-05-01 | 2011-08-31 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
TW200738682A (en) * | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
AU2007273057A1 (en) | 2006-07-12 | 2008-01-17 | Merck Sharp & Dohme Corp. | Substituted pyrazoles as ghrelin receptor antagonists |
UA103633C2 (ru) | 2008-09-24 | 2013-11-11 | Басф Се | Пиразольные соединения для борьбы с бесхребетными вредителями |
JP2015096499A (ja) * | 2013-10-11 | 2015-05-21 | 田辺三菱製薬株式会社 | 医薬組成物 |
SG11201607895PA (en) * | 2014-05-28 | 2016-12-29 | Novartis Ag | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors |
EP3374361A1 (en) * | 2015-11-13 | 2018-09-19 | Novartis AG | Novel pyrazolo pyrimidine derivatives |
ES2862922T3 (es) | 2016-12-21 | 2021-10-08 | Mereo Biopharma 3 Ltd | Uso de anticuerpos antiesclerostina en el tratamiento de la osteogénesis imperfecta |
US10858364B2 (en) | 2016-12-21 | 2020-12-08 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of Bruton's tyrosine kinase |
TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為malt1抑制劑之吡唑衍生物 |
JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
-
2017
- 2017-12-19 TW TW106144535A patent/TWI795381B/zh active
- 2017-12-20 AU AU2017382185A patent/AU2017382185C1/en active Active
- 2017-12-20 TN TNP/2019/000192A patent/TN2019000192A1/en unknown
- 2017-12-20 CA CA3048027A patent/CA3048027A1/en active Pending
- 2017-12-20 EP EP17851862.7A patent/EP3558969A1/en active Pending
- 2017-12-20 KR KR1020197021137A patent/KR102583317B1/ko active IP Right Grant
- 2017-12-20 CN CN201780079706.3A patent/CN110214136A/zh active Pending
- 2017-12-20 EA EA201991503A patent/EA201991503A1/ru unknown
- 2017-12-20 UA UAA201908268A patent/UA127920C2/uk unknown
- 2017-12-20 BR BR112019012355A patent/BR112019012355A2/pt unknown
- 2017-12-20 MA MA047125A patent/MA47125A/fr unknown
- 2017-12-20 PE PE2019001288A patent/PE20191755A1/es unknown
- 2017-12-20 MX MX2019007540A patent/MX2019007540A/es unknown
- 2017-12-20 US US15/847,999 patent/US10954214B2/en active Active
- 2017-12-20 WO PCT/US2017/067516 patent/WO2018119036A1/en unknown
- 2017-12-20 JP JP2019533465A patent/JP7138641B2/ja active Active
- 2017-12-21 UY UY0001037537A patent/UY37537A/es unknown
- 2017-12-21 AR ARP170103626A patent/AR110421A1/es unknown
-
2019
- 2019-05-31 PH PH12019501212A patent/PH12019501212A1/en unknown
- 2019-06-13 IL IL267343A patent/IL267343B2/en unknown
- 2019-06-19 CL CL2019001709A patent/CL2019001709A1/es unknown
- 2019-06-21 MX MX2022005827A patent/MX2022005827A/es unknown
- 2019-06-21 CO CONC2019/0006622A patent/CO2019006622A2/es unknown
-
2020
- 2020-11-25 US US17/104,081 patent/US20220315557A1/en active Pending
-
2022
- 2022-02-28 AU AU2022201352A patent/AU2022201352A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2017382185A1 (en) | 2019-06-13 |
US20180170909A1 (en) | 2018-06-21 |
WO2018119036A1 (en) | 2018-06-28 |
EA201991503A1 (ru) | 2019-11-29 |
CO2019006622A2 (es) | 2019-06-28 |
EP3558969A1 (en) | 2019-10-30 |
AU2017382185B2 (en) | 2021-12-02 |
AR110421A1 (es) | 2019-03-27 |
UY37537A (es) | 2018-06-29 |
CA3048027A1 (en) | 2018-06-28 |
JP2020514267A (ja) | 2020-05-21 |
UA127920C2 (uk) | 2024-02-14 |
PH12019501212A1 (en) | 2019-12-16 |
IL267343A (en) | 2019-08-29 |
US20220315557A1 (en) | 2022-10-06 |
IL267343B2 (en) | 2023-06-01 |
AU2022201352A1 (en) | 2022-03-24 |
MX2019007540A (es) | 2019-10-24 |
AU2017382185C9 (en) | 2022-08-04 |
AU2017382185C1 (en) | 2022-08-11 |
TWI795381B (zh) | 2023-03-11 |
PE20191755A1 (es) | 2019-12-12 |
KR20190093669A (ko) | 2019-08-09 |
JP7138641B2 (ja) | 2022-09-16 |
US10954214B2 (en) | 2021-03-23 |
TN2019000192A1 (en) | 2020-10-05 |
TW201835067A (zh) | 2018-10-01 |
MA47125A (fr) | 2021-04-28 |
BR112019012355A2 (pt) | 2019-11-26 |
CN110214136A (zh) | 2019-09-06 |
CL2019001709A1 (es) | 2019-10-04 |
KR102583317B1 (ko) | 2023-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005827A (es) | Derivados de pirazol como inhibidores de malt1. | |
PH12020552207A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
MX2020007265A (es) | Derivados de rapamicina. | |
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
PH12020552206A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
WO2019035863A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | |
MX2021004659A (es) | Derivados de aminopirimidina/pirazina como inhibidores de ctps1. | |
TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
PH12017500653A1 (en) | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes | |
EA201990400A1 (ru) | Соединения и композиции и их применение | |
MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
PH12016501613A1 (en) | Pyrazines modulators of gpr6 | |
WO2018166993A3 (en) | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | |
MX2019002017A (es) | Derivados de sofosbuvir para el tratamiento de la hepatitis c. | |
MX2016011630A (es) | Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii. | |
MX2021012417A (es) | Anillos de piridina que contienen derivados como inhibidores de malt1. | |
WO2018211324A8 (en) | Prodrugs for the treatment of disease | |
MX2023001906A (es) | Diarilureas como moduladores alostericos de cannabinoide cb1. | |
EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |